Nizubaglustat
AssetAlso AZ-3102
Brain-penetrant azasugar that interferes with glycosphingolipid metabolism through a dual mode of action.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- 3
- Indications
- 0
- Trials
- 1
- Developer
Indications
3GM1 and GM2 gangliosidoses
Phase 3, azafaros.com, 7 Oct 2026
GM2 gangliosidosis
Phase 3, azafaros.com, 10 Oct 2026
Niemann-Pick type c
Phase 3, azafaros.com, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Evidence for its targets2
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.